Adopting Next-Generation Conjugation Chemistries Beyond Maleimide to Eliminate In Vivo Retro-Michael Deconjugation for Substantially Reduced Pre-Tumoral Payload Loss & Systemic Toxicity
- Leveraging site-selective enzymatic conjugation platforms that recognize native peptide motifs to achieve precise, uniform drug attachment, resulting in ADCs with minimized reduced pre‑tumoral payload loss
- Understanding improvements in enhanced stability over maleimides, to overcome the instability and premature payload release associated with traditional maleimides, increasing in vivo linker durability and lowered systemic toxicity
- Expanding enzymatic conjugation repertoires capable of installing tunable, stimuli-responsive cleavage motifs to fine‑tune payload liberation, enabling highly controlled, tumor-selective drug release